Reportlinker Adds Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
NEW YORK, March 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Description
Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
"Atherosclerosis Or Coronary Artery Disease (CAD) – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global atherosclerosis market. The report identifies the key trends shaping and driving the global atherosclerosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global atherosclerosis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
<bScope
The <bScope of the report includes:
- Annualized global atherosclerosis revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global atherosclerosis market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with atherosclerosis.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global atherosclerosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global atherosclerosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global atherosclerosis market landscape? – Identify, understand and capitalize.
Companies Mentioned
GlaxoSmithKline plc
Novartis AG
Merck & Co., Inc
Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Coronary Artery Disease: Market Characterization 6
2.1 Overview 6
2.2 Coronary Artery Disease Market Size 6
2.3 Coronary Artery Disease Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Coronary Artery Disease Market 9
2.4.1 Drivers of the Coronary Artery Disease Market 9
2.4.2 Barriers for the Coronary Artery Disease Market 9
2.5 Opportunity and Unmet Need 10
2.6 Key Takeaway 10
3 Coronary Aartery Disease: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Coronary Artery Disease Market 12
3.3.1 Lipitor 12
3.3.2 Crestor 12
3.3.3 Plavix 13
3.3.4 Pravachol (pravastatin sodium) 14
3.3.5 Niaspan (Niacin) 14
3.4 Key Takeaway 16
4 Coronary Artery Disease: Pipeline Assessment 17
4.1 Overview 17
4.2 Strategic Pipeline Assessment 17
4.2.1 Technology Trends Analytic Framework 17
4.3 Coronary Artery Disease Therapeutics – Promising Drugs under Clinical Development 18
4.4 Drugs under Clinical Development 19
4.4.1 Darapladib 19
4.4.2 Anacetrapib 19
4.4.3 Aliskiren 20
4.4.4 SCH 530348 21
4.5 Coronary Artery Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action 22
4.6 Coronary Artery Disease Pipeline – Pipeline by Clinical Phases of Development 23
4.6.1 Coronary Artery Disease Therapeutics – Phase III Clinical Pipeline 23
4.6.2 Coronary Artery Disease Therapeutics – Phase II Clinical Pipeline 24
4.6.3 Coronary Artery Disease Therapeutics – Phase I Clinical Pipeline 24
4.6.4 Coronary Artery Disease Therapeutics – Preclinical Pipeline 25
4.7 Discontinued / Suspended Drugs for Coronary Artery Disease 25
4.8 Key Takeaway 25
5 Coronary Artery Disease Market: Implications for Future Market Competition 26
6 Coronary Artery Disease Market: Future Players in the Cornary Artery Disease Market 27
6.1 Introduction 27
6.2 GlaxoSmithKline plc 27
6.2.1 Overview 27
6.2.2 Business Description 28
6.2.3 Cardiovascular Portfolio 30
6.2.4 Coronary Artery Disease Product Portfolio 30
6.3 Novartis AG 31
6.3.1 Overview 31
6.3.2 Business Description 31
6.3.3 Cardiovascular Portfolio 32
6.3.4 Coronary Artery Disease Product Portfolio 32
6.4 Merck & Co., Inc. 33
6.4.1 Overview 33
6.4.2 Business Description 33
6.4.3 Cardiovascular Portfolio 34
6.4.4 Coronary Artery Disease product portfolio 35
7 Coronary Artery Disease: Appendix 37
7.1 Definitions 37
7.2 Acronyms 37
7.3 Research Methodology 38
7.3.1 Coverage 39
7.3.2 Secondary Research 39
7.3.3 Forecasting 40
7.3.4 Primary Research 43
7.3.5 Expert Panels 43
7.4 Contact Us 43
7.5 Disclaimer 43
7.6 Sources 44
List of Tables
1.1 List of Tables
Table 1: Global Coronary Artery Disease Market Revenue ($bn), 2001-2009 7
Table 2: Global Coronary Artery Disease Market Forecast ($bn), 2009-2016 8
Table 3: Major Marketed Products in the Coronary Artery Disease Market, 2010 15
Table 4: Coronary Artery Disease Therapeutics –Promising Drugs Under Clinical Development, 2010 18
Table 5: Coronary Artery Disease Therapeutics – Phase III Clinical Pipeline, 2010 23
Table 6: Coronary Artery Disease Therapeutics – Phase II Clinical Pipeline, 2010 24
Table 7: Coronary Artery Disease Therapeutics – Phase I Clinical Pipeline, 2010 24
Table 8: Coronary Artery Disease Therapeutics – Preclinical Pipeline, 2010 25
Table 9: List of Discontinued Drugs for Coronary Artery Disease, 2010 25
Table 10: GlaxoSmithKline plc – Cardiovascular and Coronary Artery Disease Pipeline, 2010 30
Table 11: Novartis AG – Cardiovascular and Coronary Artery Disease Pipeline, 2010 32
Table 12: Merck & Co., Inc. – Cardiovascular and Coronary Artery Disease Pipeline, 2010 34
List of Figures
1.2 List of Figures
Figure 1: Global Coronary Artery Disease Market Revenue ($bn), 2001–2009 7
Figure 2: Global Coronary Artery Disease Market Forecast ($bn), 2009-2016 8
Figure 3: Opportunity and Unmet Need in the Coronary Artery Disease Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Coronary Artery Disease, 2010 11
Figure 5: Technology Trends Analytic Framework of the Coronary Artery Disease Pipeline, 2010 17
Figure 6: Technology Trends Analytic Framework of Coronary Artery Disease Pipeline – Description, 2010 18
Figure 7: Coronary Artery Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 22
Figure 8: Coronary Artery Disease Pipeline by Phase of Clinical Development, 2010 23
Figure 9: Implications for Future Market Competition in the Coronary Artery Disease Market, 2010 26
Figure 10: Coronary Artery Disease Therapeutics Market – Clinical Pipeline by Company, 2010 27
Figure 11: GlobalData Methodology 39
Figure 12: GlobalData Market Forecasting Model 42
To order this report:
Pharmaceutical Industry: Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
Check our Company Profile, SWOT and Revenue Analysis!
Contact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article